Achema middle east

Cmed to Demonstrate how encapsia® Transforms Clinical Trial Data Management, Capture and Reporting at Leading Oncology Meetings

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.
- Advertisement -

Cmed, an oncology focused, innovative technology-led CRO, announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Clinical Operations in Oncology Trials Europe, taking place 5-6 December in Munich, Germany, and the ASH Annual Meeting, taking place 9-12 December in Atlanta, GA.

As a full-service CRO, Cmed has a strong reputation in delivering complex and demanding clinical trials across numerous oncology types, including various haematological indications, immuno-oncology, breast, lung, prostate and colorectal. Cmed has combined this deep understanding of the needs of oncology studies with its encapsia clinical data suite, allowing the company to work with sponsors to set-up and conduct trials smarter and more efficiently.
David Connelly, Chief Executive Officer, Cmed, commented: “At Cmed, with 16 years’ experience in oncology clinical trials, we truly understand the importance and practical challenges of conducting oncology clinical studies”

“During these pivotal meetings, we are excited to be able to showcase our encapsia clinical data suite and demonstrate to sponsors the benefits of immediate access to real-time clinical data with live, actionable insights and analytics. These include helping to enroll patients more accurately while bringing improvements to monitoring patient safety, generating high quality data and driving more timely decision-making.”

Visitors are invited to join Cmed at booth #15 during Clinical Operations in Oncology Trials Europe and booth #512 during the ASH Annual Meeting. To schedule a meeting
with the Cmed team, please contact info@cmedresearch.com

For further information on Cmed, please visit www.cmedresearch.com

About Cmed
Cmed is an innovative, full service technology-led CRO. Cmed brings together experienced people and technology, providing customers with a friendly, proactive service, and delivers this service using advanced clinical data capture, management and reporting software and processes. Cmed’s new generation clinical data suite, encapsia®, streamlines the capture, management and reporting of clinical data, saving customers time and money. Clinical data can be captured flexibly by eSource, multi-media and web eDC, while being displayed in live visual insights, providing live analytics, and allowing within suite audit trailed actions. It is fully compliant with regulatory guidelines, and allows integration with existing systems.

 

Latest stories

Related stories

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Aligning Scientific Innovation with Commercial Reality in Drug Development

The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.

AI-Crafted Pill Succeeds Trials of Plaque Psoriasis Patients

Takeda Pharmaceutical from Japan said on December 17, 2025,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »